SonoVue

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
05-06-2023
Produktens egenskaper Produktens egenskaper (SPC)
05-06-2023

Aktiva substanser:

sulphur hexafluoride

Tillgänglig från:

Bracco International B.V.

ATC-kod:

V08DA04

INN (International namn):

sulphur hexafluoride

Terapeutisk grupp:

Contrast media

Terapiområde:

Ultrasonography; Echocardiography

Terapeutiska indikationer:

This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography.

Produktsammanfattning:

Revision: 20

Bemyndigande status:

Authorised

Tillstånd datum:

2001-03-26

Bipacksedel

                                19
B.
PACKAGE LEAFLET
20
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SONOVUE 8 MICROLITRES/ML POWDER AND SOLVENT FOR DISPERSION FOR
INJECTION
sulphur hexafluoride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their symptoms are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What SonoVue is and what it is used for
2.
What you need to know before you are given SonoVue
3.
How SonoVue is given
4.
Possible side effects
5.
How to store SonoVue
6.
Contents of the pack and other information
1.
WHAT SONOVUE IS AND WHAT IT IS USED FOR
SonoVue is for diagnostic use only.
SonoVue is an ultrasound contrast agent that contains tiny bubbles
filled with a gas called sulphur
hexafluoride.
If you are an adult, SonoVue helps to obtain clearer ultrasound
pictures of your heart, your blood
vessels and/or tissues of the liver and breast.
SonoVue helps to obtain clearer pictures of the urinary tract in
children.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN SONOVUE
DO NOT USE SONOVUE:
-
If you are allergic to sulphur hexafluoride or any of the other
ingredients of this medicine (listed
in section 6).
-
If you have been told you have a right-to-left heart shunt.
-
If you have severe pulmonary hypertension (pulmonary artery pressure >
90mmHg).
-
If you have uncontrolled hypertension.
-
If you have adult respiratory distress syndrome (a severe, medical
condition characterized by
widespread inflammation in the lungs).
-
If you have been told not to take dobutamine (medicine that stimulates
the heart) due to your
severe heart disease.
WARNINGS AND PRECAUTIONS
Please tell your doctor if in the past 2 days you h
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
SonoVue 8 microlitres/mL powder and solvent for dispersion for
injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each mL of the dispersion contains 8 µL sulphur hexafluoride
microbubbles, equivalent to
45 micrograms.
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Powder and solvent for dispersion for injection.
White powder
Clear, colourless solvent
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
This medicinal product is for diagnostic use only.
SonoVue is for use with ultrasound imaging to enhance the echogenicity
of the blood, or of fluids in
the urinary tract which results in an improved signal to noise ratio.
SonoVue should only be used in patients where study without contrast
enhancement is inconclusive.
Echocardiography
SonoVue is a transpulmonary echocardiographic contrast agent for use
in adult patients with suspected
or established cardiovascular disease to provide opacification of
cardiac chambers and enhance left
ventricular endocardial border delineation.
Doppler of macrovasculature
SonoVue increases the accuracy in detection or exclusion of
abnormalities in cerebral arteries and
extracranial carotid or peripheral arteries in adult patients by
improving the Doppler signal to noise
ratio.
SonoVue increases the quality of the Doppler flow image and the
duration of clinically-useful signal
enhancement in portal vein assessment in adult patients.
Doppler of microvasculature
SonoVue improves display of the vascularity of liver and breast
lesions during Doppler sonography in
adult patients leading to more specific lesion characterisation.
Ultrasonography of excretory urinary tract
SonoVue is indicated for use in ultrasonography of the excretory tract
in paediatric patients from
newborn to 18 years to detect vesicoureteral reflux. For the
limitation in the interpretation of a
negative urosonography, see section 4.4. and 5.1.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
This product should only be u
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 05-06-2023
Produktens egenskaper Produktens egenskaper bulgariska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 24-08-2017
Bipacksedel Bipacksedel spanska 05-06-2023
Produktens egenskaper Produktens egenskaper spanska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 24-08-2017
Bipacksedel Bipacksedel tjeckiska 05-06-2023
Produktens egenskaper Produktens egenskaper tjeckiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 24-08-2017
Bipacksedel Bipacksedel danska 05-06-2023
Produktens egenskaper Produktens egenskaper danska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 24-08-2017
Bipacksedel Bipacksedel tyska 05-06-2023
Produktens egenskaper Produktens egenskaper tyska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 24-08-2017
Bipacksedel Bipacksedel estniska 05-06-2023
Produktens egenskaper Produktens egenskaper estniska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 24-08-2017
Bipacksedel Bipacksedel grekiska 05-06-2023
Produktens egenskaper Produktens egenskaper grekiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 24-08-2017
Bipacksedel Bipacksedel franska 05-06-2023
Produktens egenskaper Produktens egenskaper franska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 24-08-2017
Bipacksedel Bipacksedel italienska 05-06-2023
Produktens egenskaper Produktens egenskaper italienska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 24-08-2017
Bipacksedel Bipacksedel lettiska 05-06-2023
Produktens egenskaper Produktens egenskaper lettiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 24-08-2017
Bipacksedel Bipacksedel litauiska 05-06-2023
Produktens egenskaper Produktens egenskaper litauiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 24-08-2017
Bipacksedel Bipacksedel ungerska 05-06-2023
Produktens egenskaper Produktens egenskaper ungerska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 24-08-2017
Bipacksedel Bipacksedel maltesiska 05-06-2023
Produktens egenskaper Produktens egenskaper maltesiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 24-08-2017
Bipacksedel Bipacksedel nederländska 05-06-2023
Produktens egenskaper Produktens egenskaper nederländska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 24-08-2017
Bipacksedel Bipacksedel polska 05-06-2023
Produktens egenskaper Produktens egenskaper polska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 24-08-2017
Bipacksedel Bipacksedel portugisiska 05-06-2023
Produktens egenskaper Produktens egenskaper portugisiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 24-08-2017
Bipacksedel Bipacksedel rumänska 05-06-2023
Produktens egenskaper Produktens egenskaper rumänska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 24-08-2017
Bipacksedel Bipacksedel slovakiska 05-06-2023
Produktens egenskaper Produktens egenskaper slovakiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 24-08-2017
Bipacksedel Bipacksedel slovenska 05-06-2023
Produktens egenskaper Produktens egenskaper slovenska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 24-08-2017
Bipacksedel Bipacksedel finska 05-06-2023
Produktens egenskaper Produktens egenskaper finska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 24-08-2017
Bipacksedel Bipacksedel svenska 05-06-2023
Produktens egenskaper Produktens egenskaper svenska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 24-08-2017
Bipacksedel Bipacksedel norska 05-06-2023
Produktens egenskaper Produktens egenskaper norska 05-06-2023
Bipacksedel Bipacksedel isländska 05-06-2023
Produktens egenskaper Produktens egenskaper isländska 05-06-2023
Bipacksedel Bipacksedel kroatiska 05-06-2023
Produktens egenskaper Produktens egenskaper kroatiska 05-06-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 24-08-2017

Sök varningar relaterade till denna produkt

Visa dokumenthistorik